Mylan N.V. (Viatris) — Ethics Grade D

Mylan N.V. (Viatris) receives an overall ethics grade of D (32/100) on CancelCo's corporate accountability database. Sector: Pharmaceuticals. Market cap: Large Cap.

Category scores

• labor: 55
• privacy: 80
• consumer: 20
• environment: 65
• humanRights: 45

Documented incidents (3)

• EpiPen Price Gouging (high, 2016) — Mylan faced intense public scrutiny and congressional hearings after raising the price of a life-saving EpiPen two-pack by over 400%, from roughly $100 to over $600.
• Medicaid Rebate Fraud (high, 2017) — The company misclassified EpiPen as a generic drug rather than a branded drug to pay lower rebates to the Medicaid program for years.
• Generic Drug Price Fixing (high, 2019) — Mylan was named in a major multi-state lawsuit alleging a conspiracy among generic pharmaceutical manufacturers to artificially inflate and manipulate prices of various drugs.

Documented good deeds

• Global HIV Healthcare Access — As Viatris, the company remains a leading supplier of antiretroviral therapies for HIV/AIDS in low-income countries.

Ethical alternatives

• Civica Rx — A non-profit drug company focused on stabilizing the supply and price of essential medicines.